Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity.

Abstract: An improved method for producing a cationic liposomal preparation comprising a camptothecin drug with enhanced physical and chemical stability, a cationic liposomal preparation obtainable by this method and pharmaceutical compositions thereof are disclosed.

Abstract: The present invention relates to a non-vesicular preparation comprising at least one cationic amphiphile in an aqueous environment, its production and use and a cationic liposome suspension obtainable thereof with increase drug trap ratio and its areas of application such as pharmacology and medicine, particularly its use as carrier system for active substances.

Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.

Abstract: The present invention relates to a method of stabilizing a low molecular weight compound in a cationic liposome, wherein said compound has a low solubility in a lipid membrane and/or a low permeability across a lipid membrane. Preferrably, the compound is modified in order to increase lipid membrane solubility and/or lipid membrane permeability. After delivery of the cationic liposome to a target site, particularly a target site in an organism, the modification is reversed and the low molecular weight compound may enact its desired activity.

Abstract: New boron icosahedral ethers and esters formed from Cs2[closo-B12(OH)12],; Cs[closo-1-H-1-CB11(OH)11]; and closo-1,12-H2-1,12-C2B10(OH)10 are disclosed. Also set forth are their preparation by reacting the icosahedral boranes [closo-B12H12]2−, [closo-1-CB11H12]− and closo-1,12-(CH2OH)2-1,12-C2B10H10 with an acid anhdride or acid chloride to form the ester or an alkylating agent to form the ether.

Abstract: The dodecamethyl closo-borane dianion [closo-B12(CH3)12]2− and anion [closo-B12(CH3)12]− were synthesized and characterized. Dodecamethyl-closo dodecaborate (2−) was produced from [closo-B12H12]2−, using trimethylaluminum, and methyl iodide and modified Friedel-Crafts reaction conditions. The anion was produced from the dianion by chemical oxidation using ceric (4) ammonium nitrate in acetonitrile. The anion and dianion were both characterized by 1H and 11B NMR spectroscopy, high-resolution fast atom bombardment (FAB) mass spectrometry, cyclic voltammetry, and single-crystal X-ray diffraction. The “camouflaged” polyhedral borane anion [closo-B12(CH3)12]2−, can be used as a precursor to materials that offer a broad spectrum of novel applications ranging from drug applications and supramolecular chemistry to use as a weakly-coordinating dianion.

Abstract: New icosahedral borohydrates Cs2[closo-B12(OH)12]; Cs[closo-1-H-1-CB11(OH)11]; and closo-1,12-H2-1,12-C2B10(OH)10 are disclosed. Also set forth are their preparation by refluxing the icosahedral boranes [closo-B12H12]2−, [closo-1-CB11H12]− and closo-1,12-(CH2OH)2-1,12-C2B10H10 with a hydroxylating agent, preferably 30%w hydrogen peroxide.